Novo Nordisk (NYSE:NVO) is one of the globe's biggest drug companies. It's a major player in providing diabetes treatments and is often included in dividend portfolios.
However, patent expirations and new drugs from competitors such as Eli Lilly (NYSE:LLY) are pressuring Novo to spend more on its research pipeline. As a result, dividend investors are right to question whether the risk of sliding sales threatens Novo's dividend payout.
In the following slideshow you'll see whether I think Novo's dividend is safe and gain insight into how the company's dividend yield matches up with industry peers Eli Lilly and AstraZeneca (NYSE:AZN).
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.